Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Pulmonary-Allergy Drugs Advisory Committee

Executive Summary

Will discuss Warner-Lambert's NDA for Pro-Air (procaterol) metered- dose inhaler on Feb. 25 and the NDA for Glaxo's Serevent (salmeterol xinafoate) inhalation on Feb. 26. The discussion of the two beta agonists for treatment of asthma follows up on the committee's December 1991 conclusion that more study was needed on the association of increased mortality and morbidity with bet agonist use. The meeting will take place at Parklawn.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel